Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,321 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: docetaxel Clear all
Terminated Phase 2Phase 3 Interventional Results available

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

NCT01603420
View directory record Official record
Conditions
Prostate Cancer
Interventions
Luteinizing hormone-releasing hormone (LHRH), Docetaxel, Conformal Radiation Therapy (RT)
Drug · Other
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years to 75 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Warrenville, Illinois • Oklahoma City, Oklahoma • Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

NCT00417079
View directory record Official record
Conditions
Neoplasms, Prostatic Neoplasms
Interventions
cabazitaxel (XRP6258) (RPR116258), mitoxantrone, prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

NCT00268918
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer
Interventions
Docetaxel, PTK787
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 30, 2026, 2:37 PM EDT
Terminated Phase 2 Interventional Results available

Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores

NCT00832338
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Cancer of the Breast
Interventions
Docetaxel with Cytoxan, Dexamethasone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

Avastin and Taxotere for Esophagogastric Cancer

NCT00137813
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Docetaxel, Bevacizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02574078
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Bevacizumab, Pemetrexed, Best Supportive Care, nab-Paclitaxel, Paclitaxel, Docetaxel, Gemcitabine, Erlotinib, Crizotinib, Carboplatin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
133
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 30, 2026, 2:37 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

NCT04721015
View directory record Official record
Conditions
Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)
Interventions
ABBV-637, Docetaxel, Osimertinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • Huntersville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 30, 2026, 2:37 PM EDT
Active, not recruiting Phase 3 Interventional

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

NCT03801876
View directory record Official record
Conditions
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Thoracic Esophagus Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Docetaxel, Esophagectomy, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Paclitaxel, Positron Emission Tomography, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2036
U.S. locations
96
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

NCT00186277
View directory record Official record
Conditions
Bladder Cancer
Interventions
Oxaliplatin, Taxotere
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2011 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

NCT01492101
View directory record Official record
Conditions
Locally Recurrent Breast Cancer, Metastatic Breast Cancer
Interventions
NKTR-102, Treatment of Physician's Choice (TPC)
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
88
States / cities
Flagstaff, Arizona • Burbank, California • Los Angeles, California + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 30, 2026, 2:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

NCT07590934
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel, AZD2287 (Imaging agent)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Duarte, California • Encino, California • South Pasadena, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 2:37 PM EDT
Not listed Phase 2 Interventional

Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy

NCT04467801
View directory record Official record
Conditions
NSCLC Stage IV, NSCLC Stage IIIB
Interventions
Ipatasertib
Drug
Lead sponsor
Jun Zhang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer

NCT01565928
View directory record Official record
Conditions
Prostate Cancer
Interventions
MDV3100
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
New York, New York • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors

NCT01183364
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
STA-9090 (ganetespib) with Docetaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 1Phase 2 Interventional

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

NCT04381832
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant
Interventions
Etrumadenant, Zimberelimab, Quemliclustat, Enzalutamide, Docetaxel, SG
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
17
States / cities
Cerritos, California • Encino, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 30, 2026, 2:37 PM EDT
Terminated Phase 2 Interventional Results available

Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC

NCT00801801
View directory record Official record
Conditions
Non Squamous Cell Lung Cancer, Non Small Cell Lung Cancer
Interventions
Docetaxel + Sorafenib
Drug
Lead sponsor
Francisco Robert,MD
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer

NCT00692900
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
intravenous docetaxel with intraperitoneal oxaliplatin, intravenous oxaliplatin with intraperitoneal docetaxel
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 30, 2026, 2:37 PM EDT
Terminated Phase 1Phase 2 Interventional

Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer

NCT00293371
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, prednisone, vatalanib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

NCT03043807
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide Acetate, Docetaxel, Bicalutamide, Radiation, Abiraterone Acetate
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 30, 2026, 2:37 PM EDT
Recruiting Phase 3 Interventional

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT05281471
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
Interventions
olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Mobile, Alabama • Tucson, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers

NCT00169000
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Docetaxel
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 6, 2009 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

NCT00630032
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, Docetaxel, epirubicin hydrochloride, fluorouracil, ixabepilone
Drug
Lead sponsor
UNICANCER
Other
Eligibility
18 Years and older · Female only
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
17
States / cities
Scottsdale, Arizona • Denver, Colorado • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer

NCT00030407
View directory record Official record
Conditions
Lung Cancer
Interventions
Celecoxib, Docetaxel
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 30, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes

NCT00953420
View directory record Official record
Conditions
Nasopharyngeal Carcinoma
Interventions
Docetaxel, Carboplatin, Dexamethasone, EBV-specific cytotoxic T lymphocytes, G-CSF or Peg-GCSF
Drug · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 30, 2026, 2:37 PM EDT